Company Description
Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases.
The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence.
Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes.
The company is headquartered in Alameda, California.
| Country | United States |
| Founded | 1998 |
| IPO Date | Nov 19, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Adam Mendelsohn |
Contact Details
Address: 1350 South Loop Road Alameda, California 94502 United States | |
| Phone | 415 506 8462 |
| Website | vivani.com |
Stock Details
| Ticker Symbol | VANI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001266806 |
| CUSIP Number | 92854B109 |
| ISIN Number | US92854B1098 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Adam Mendelsohn Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Truc Le M.B.A. | Chief Operations Officer |
| Dr. Lisa E. Porter M.D. | Chief Medical Officer |
| Donald Dwyer M.B.A. | Chief Business Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Oct 22, 2024 | 8-K | Current Report |
| Sep 26, 2024 | 8-K | Current Report |
| Sep 23, 2024 | 8-K | Current Report |
| Sep 4, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Jul 11, 2024 | 8-K | Current Report |
| Jun 28, 2024 | 8-K | Current Report |